NASDAQ:LIMN Liminatus Pharma Q2 2025 Earnings Report $0.15 0.00 (-0.33%) Closing price 04:00 PM EasternExtended Trading$0.15 0.00 (-0.13%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Liminatus Pharma EPS ResultsActual EPS-$0.05Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ALiminatus Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALiminatus Pharma Announcement DetailsQuarterQ2 2025Date10/4/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Liminatus Pharma Earnings HeadlinesLiminatus Pharma secures $1.9M cash via warrant exercisesJune 3 at 1:03 PM | msn.comLiminatus Pharma Enters Into Warrant Exercise Transaction for $1.9 Million in Gross ProceedsJune 3 at 8:30 AM | globenewswire.comSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. But at a $1.75 trillion valuation and 266 times earnings, early institutional holders may be looking for someone to sell to. Dylan Jovine has identified a small company in Musk's supply chain that builds the power infrastructure behind Colossus - still trading at a fraction of its potential value. No IPO allocation required.June 4 at 1:00 AM | Behind the Markets (Ad)Liminatus Pharma Announces Proposed Merger with InnocsAI to Expand Oncology Cell Therapy PipelineMay 22, 2026 | theglobeandmail.comLiminatus Pharma is trending overnight — here's why LIMN stock surged over 79% in after-hours sessionMay 22, 2026 | msn.comLiminatus Pharma Announces Nasdaq Delisting NotificationMay 21, 2026 | globenewswire.comSee More Liminatus Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Liminatus Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Liminatus Pharma and other key companies, straight to your email. Email Address About Liminatus PharmaLiminatus Pharma (NASDAQ:LIMN), Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.View Liminatus Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro in FocusMedtronic Bottoms, Healthy Rebound AheadFrom Runway to Riches: Victoria's Secret's New LookDell's AI Toll Bridge Is Paved with Record MarginsGitLab’s Price Recovery Gains Traction—Time to Get On Board?Ulta's Q1 Report Primes It for a Beauty of a ReboundPalo Alto Networks Accelerates Growth 31% on AI Demand Upcoming Earnings Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
